As news that Mylan will make available a generic version of its own brand-name product, KHN answers key questions about how this development could affect consumers.
Research shows exercise-based cardiac rehab programs help heart patients heal faster and live longer. But fewer than a third take part. Time and cost are the main barriers, doctors and patients say.
Insurance claims for medical services related to opioid dependence diagnoses rose more than 3,000 percent between 2007 and 2014, an analysis finds.
Federal spending has soared for drugs that are handmade in local pharmacies, and federal investigators are raising concerns about fraud or overbilling.
The case alleges that insured consumers were overcharged because of a contract agreement.
After once being considered a preferred vaccine option for children, a CDC advisory panel recommended the spray should not be used in the upcoming flu season.
The U.S Preventive Services Task Force recently expanded the list of approved colorectal cancer screening tests. Here’s a primer on these various tests and how they might be covered now and in the future by health insurance.
Amid growing concern about rising drug costs, the practices of prescription benefit management firms are drawing a new level of attention.
The Medicare Payment Advisory Commission outlined a package of changes to Medicare’s drug program that could save billions of dollars.
A proposal to change the way Medicare pays for some drugs has set off intense reaction and lobbying — all tied to a common theme: How far should the government go in setting prices for prescription drugs?
The federal agency says the wellness programs can get health details about workers and their spouses as long as the financial rewards or penalties do not exceed 30 percent of the cost for an individual in the company’s group health plan.
Gina McCarthy met with Kaiser Health News to answer a range of questions, including how the agency is involved in efforts to combat Zika and the ongoing water crisis in Flint, Michigan.
The proposal that Medicare made this month to better control prescription drug costs involves testing strategies used with some success in the private sector.
The Department of Health and Human Services issues new rules designed to simplify health coverage consumers buy through Healthcare.gov.
Regulators unveiled a two-part plan that will change payments and test ways in which the Medicare Part B program can change the incentives that some policy experts say encourage doctors to choose higher-cost medications.
A market is emerging for products that enlist data and technology to identify patients who might be at risk for hospitalization or readmission.
Agency For Healthcare Research and Quality data show that more women with breast cancer are opting for mastectomies over less-invasive options, and more are having the procedure in outpatient facilities where they don’t spend even one night in the hospital.
The decision by Independence Blue Cross of Pennsylvania to pay for whole genome sequencing for some cancer patients adds to the debate about how to handle these expensive tests.
Some medicines, particularly intravenous treatments, are not listed in plans’ pharmacy benefit section and, therefore, it’s difficult to confirm coverage specifics.
In a recent interview, Cordani discussed the evolution of exchange health plans as well the proposed merger between Cigna and Anthem.